# Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Chigusa Morizane,Takuji Okusaka,Junki Mizusawa,Hiroshi Katayama,Makoto Ueno,Masafumi Ikeda,Masato Ozaka,Naohiro Okano,Kazuya Sugimori,Akira Fukutomi,Hiroki Hara,Nobumasa Mizuno,Hiroaki Yanagimoto,Keita Wada,Kazutoshi Tobimatsu,Kei Yane,Shoji Nakamori,Hiroyuki Yamaguchi,Akinori Asagi,Seigo Yukisawa,Yasushi Kojima,Ken Kawabe,Yasuyuki Kawamoto,Rie Sugimoto,Tomohisa Iwai,Kazuyoshi Nakamura,Hiroyoshi Miyakawa,Tatsuya Yamashita,A. Hosokawa,Tatsuya Ioka,Naoya Kato,Kazuhiko Shioji,Kyoko Shimizu,Toshio Nakagohri,Ken Kamata,Hiroshi Ishii,Junji Furuse |
| Citations | 338 |
| DOI | 10.1093/annonc/mdz402 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2977982707 |
| PMID | 31566666 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Kazuya Sugimori](https://scholariq.org/researchers/kazuya-sugimori/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

## Paper topics

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.